- Home
- BREA vs ABP Comparison
BREA vs ABP Comparison
Compare BREA & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- ABP
- Stock Information
- Founded
- BREA 2022
- ABP 2004
- Country
- BREA Ireland
- ABP United States
- Employees
- BREA N/A
- ABP N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- ABP Health Care
- Exchange
- BREA Nasdaq
- ABP Nasdaq
- Market Cap
- BREA 13.6M
- ABP 15.5M
- IPO Year
- BREA 2023
- ABP N/A
- Fundamental
- Price
- BREA $6.88
- ABP $0.21
- Analyst Decision
- BREA
- ABP Strong Buy
- Analyst Count
- BREA 0
- ABP 1
- Target Price
- BREA N/A
- ABP $4.00
- AVG Volume (30 Days)
- BREA 18.5K
- ABP 5.6M
- Earning Date
- BREA 01-03-2025
- ABP 08-18-2025
- Dividend Yield
- BREA N/A
- ABP N/A
- EPS Growth
- BREA N/A
- ABP N/A
- EPS
- BREA N/A
- ABP N/A
- Revenue
- BREA $2,988,009.00
- ABP $183,000.00
- Revenue This Year
- BREA N/A
- ABP N/A
- Revenue Next Year
- BREA N/A
- ABP N/A
- P/E Ratio
- BREA N/A
- ABP N/A
- Revenue Growth
- BREA 151.51
- ABP 88.66
- 52 Week Low
- BREA $5.00
- ABP $0.15
- 52 Week High
- BREA $19.50
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- BREA 96.66
- ABP N/A
- Support Level
- BREA $0.66
- ABP N/A
- Resistance Level
- BREA $0.79
- ABP N/A
- Average True Range (ATR)
- BREA 0.20
- ABP 0.00
- MACD
- BREA 0.39
- ABP 0.00
- Stochastic Oscillator
- BREA 84.50
- ABP 0.00
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.